Quantitative analysis for Unicycive Therapeutics, Inc. (UNCY) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (16.0) (grade F). 27 signals analyzed (23 differentiated alt-data).
UNCY stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $7.28 | $7.05 | $7.16 |
| 2026-05-11 | $8.12 | $7.90 | $7.95 |
| 2026-05-21 | $7.74 | $7.35 | $7.63 |
| 2026-06-03 | $7.41 | $7.10 | $7.20 |
| 2026-06-15 | $7.68 | $7.07 | $7.12 |
| 2026-06-26 | $8.40 | $6.75 | $7.13 |
| 2026-07-09 | $5.50 | $5.25 | $5.26 |
| 2026-07-21 | $5.87 | $5.41 | $5.69 |
| 2026-07-31 | $5.29 | $4.98 | $5.01 |
| 2026-08-12 | $5.53 | $5.04 | $5.39 |
| 2026-08-24 | $5.64 | $5.26 | $5.34 |
| 2026-09-03 | $5.34 | $5.08 | $5.30 |
How Unicycive Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| IMDX | Insight Molecular Diagnostics Inc. | $166M | — |
| PLYX | Polaryx Therapeutics, Inc. Common Stock | $160M | — |
| ORMP | Oramed Pharmaceuticals Inc. | $173M | — |
| APYX | Apyx Medical Corporation | $159M | — |
View all Health Care stocks by valuation and signals →
Unicycive Therapeutics, Inc. (UNCY) scores Strong Sell (16.0), and the composite conceals a 83-point disagreement between its dimensions. It is strongest on competitive moat at 93 and analyst consensus at 79, and weakest on technicals at 10. A stock can carry competitive moat that high while technicals sits at 10; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 93 |
| analyst consensus | 79 |
| technicals | 10 |
StoQuant analyzes 27 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Unicycive Therapeutics, Inc. (UNCY): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/UNCY"><img src="https://stoquant.com/badge/UNCY.svg" alt="Unicycive Therapeutics, Inc. (UNCY) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.